Article Details
Retrieved on: 2021-04-20 20:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The new long-acting IL-31 program is expected to be complementary to the company's tirnovetmab monoclonal antibody program targeting IL-31, ...
Article found on: www.prnewswire.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here